# A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia

> **NCT07550387** · PHASE2 · COMPLETED · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 363 (actual)

## Conditions studied

- SCHIZOPHRENIA 1 (Disorder)

## Interventions

- **DRUG:** HS-10380 Low Dose
- **DRUG:** HS-10380 Medium dose
- **DRUG:** HS-10380 High Dose
- **DRUG:** Aripiprazole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07550387
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-23
- **Primary completion:** 2026-01-02
- **Final completion:** 2026-01-19
- **Target enrollment:** 363 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07550387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07550387, "A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07550387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*